Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RLMD |
---|---|---|
09:32 ET | 491 | 3.01 |
09:34 ET | 100 | 2.995 |
09:45 ET | 100 | 2.995 |
09:56 ET | 699 | 3.01 |
10:03 ET | 625 | 2.97 |
10:15 ET | 151 | 2.975 |
10:42 ET | 300 | 2.97 |
10:46 ET | 450 | 2.99 |
10:51 ET | 200 | 2.99 |
11:09 ET | 100 | 2.975 |
11:20 ET | 251 | 2.975 |
11:40 ET | 500 | 2.97 |
11:56 ET | 8024 | 3 |
11:58 ET | 223 | 3 |
12:14 ET | 146 | 3 |
12:23 ET | 1400 | 2.99 |
12:25 ET | 685 | 2.995 |
12:50 ET | 462 | 3 |
01:21 ET | 222 | 3.01 |
01:32 ET | 200 | 3.015 |
01:53 ET | 1000 | 3.0167 |
01:55 ET | 303 | 3.01 |
02:29 ET | 100 | 3.01 |
03:03 ET | 100 | 2.99 |
03:09 ET | 963 | 2.9828 |
03:12 ET | 3400 | 3 |
03:14 ET | 100 | 2.99 |
03:18 ET | 100 | 2.995 |
03:21 ET | 139 | 2.98 |
03:25 ET | 500 | 2.99 |
03:30 ET | 1986 | 3 |
03:32 ET | 100 | 3 |
03:43 ET | 220 | 3 |
03:45 ET | 900 | 3.02 |
03:48 ET | 347 | 3.02 |
03:50 ET | 200 | 3.02 |
03:52 ET | 2994 | 3.035 |
03:54 ET | 1943 | 3.025 |
03:56 ET | 1000 | 3.02 |
03:57 ET | 1312 | 3.01 |
03:59 ET | 9323 | 3 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Relmada Therapeutics Inc | 90.2M | -1.0x | --- |
Boundless Bio Inc | 89.0M | 0.0x | --- |
Immunic Inc | 88.3M | -0.6x | --- |
Athira Pharma Inc | 92.4M | -0.9x | --- |
Allovir Inc | 87.3M | -0.4x | --- |
Allakos Inc | 93.9M | -0.4x | --- |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $90.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-3.13 |
Book Value | $2.84 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.